The global single cell analysis market was valued at USD 2400 million in 2021 and estimated to touch USD 5050 million by 2028 growing at a CAGR of 13.2% during the forecast period 2022 to 2028. Single cell analysis is a technology helps to sequence the whole human genome at the single cell level. Single cell analysis includes proteomics, genomics, metabolomics, epigenomics, and transcriptomics. Single cell analysis is carried to analyze and measure the cellular heterogeneity and to define the specific cell type or cell state in the given population. This technique has immense applications in the field of medicine by interpreting life at fundamental level. Cancer is one of the leading causes of death worldwide. The disease has seen tremendous expansion in recent decades and is predicted to continue to do so during the forecast period. According to the Globocan 2020 information sheet, there were an anticipated 19,292,789 new cancer cases identified globally, with about 9,958,133 cancer-related deaths. Furthermore, the International Agency for Research on Cancer (IARC) predicts that by 2040, the global burden of cancer would have increased to 27.5 million new cancer cases and 16.3 million deaths. Furthermore, single-cell analysis market is projected to standardise and automate workflows in clinical diagnostics, providing significant information for real-time cancer monitoring and, eventually, new therapeutic methods for the benefit of patients. This feature is expected to result in more effective and thorough analysis. As a result, increased spending in cancer research is expected to be one of the market’s primary driving forces over the forecast period. The high cost of single-cell analysis devices, on the other hand, is projected to limit the market’s expansion.